

CURRICULUM VITAE

Wei Wei, PhD

Version Date: 1/13/2025

Contact Information:

Address 333 Cedar
Ste 115
New Haven, CT 06520
Phone: 1 (203) 737-8880
Email: wei.wei@yale.edu

School: Yale School of Medicine

Education:

08/2012 - 12/2016 PhD, Medical University of South Carolina, Biostatistics, Charleston, SC

Career/Academic Appointments:

02/2024 - 06/2026 Assistant Professor, Medical Oncology, Yale School of Medicine, New Haven, CT

Administrative Positions:

2024 - Present Interim Director of Biostatistics Shared Resource, Yale Cancer Center, Yale School of Medicine, New Haven, CT

Professional Service:

Yale University / Hospital System

Medical School

2018 - Present Committee Member, Yale Cancer Center Protocol Review Committee, The mission of the Yale Cancer Center (YCC) Protocol Review Committee (PRC), YCC's Protocol Review and Monitoring System (PRMS), is to provide ongoing review of scientific merit, priorities, and progress of YCC clinical trials. The PRMS has the authority to open protocols that meet the scientific merit and scientific priorities of the YCC and to close protocols that do not demonstrate scientific progress.

2024 - Present Committee Member, Yale Cancer Center Investigator Initiated Trials Advisory Committee, The mission of the Yale Cancer Center (YCC) Investigator Initiated Trial (IIT) Advisory Committee is to support IIT protocol development to ensure YCC-investigator initiated research is highly successful and impactful.

Bibliography:

Peer-Reviewed Original Research

1. **Wei W** , Ramos PS, Hunt KJ, Wolf BJ, Hardiman G, Chung D. GPA-MDS: A Visualization Approach to Investigate Genetic Architecture among Phenotypes Using GWAS Results. International Journal Of Genomics 2016, 2016: 6589843. [PMID: 27868058](#) , [PMCID: PMC5102874](#) , [DOI: 10.1155/2016/6589843](#) .
2. **Wei W** , Sun Z, da Silveira W, Yu Z, Lawson A, Hardiman G, Kelemen L, Chung D. Semi-supervised identification of cancer subgroups using survival outcomes and overlapping grouping information. Statistical Methods In Medical Research 2018, 28: 2137-2149. [PMID: 29336210](#) , [PMCID: PMC6922004](#) , [DOI: 10.1177/0962280217752980](#) .
3. **Wei W** , Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L. Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncology 2018, 4: e175092-e175092. [PMID: 29372234](#) , [PMCID: PMC5885272](#) , [DOI: 10.1001/jamaoncol.2017.5092](#) .
4. Wong PF, **Wei W** , Smithy JW, Acs B, Toki MI, Blenman K, Zelterman D, Kluger HM, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clinical Cancer Research 2019, 25: 2442-2449. [PMID: 30617133](#) , [PMCID: PMC6467753](#) , [DOI: 10.1158/1078-0432.ccr-18-2652](#) .
5. Wong PF, **Wei W** , Gupta S, Smithy JW, Zelterman D, Kluger HM, Rimm DL. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 194. [PMID: 31337426](#) , [PMCID: PMC6651990](#) , [DOI: 10.1186/s40425-019-0675-0](#) .
6. DeVeaux M, Kane M, **Wei W** , Zelterman D. A two-stage phase II clinical trial design with nested criteria for early stopping and efficacy. Pharmaceutical Statistics 2019, 18: 700-713. [PMID: 31507079](#) , [PMCID: PMC6996237](#) , [DOI: 10.1002/pst.1965](#) .
7. Shallis RM, Stahl M, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukhereje S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leukemia & Lymphoma 2020, 61: 1220-1225. [PMID: 32100599](#) , [PMCID: PMC8273667](#) , [DOI: 10.1080/10428194.2020.1728753](#) .
8. Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia 2020, 34: 3149-3160. [PMID: 32132655](#) , [PMCID: PMC8155811](#) , [DOI: 10.1038/s41375-020-0783-3](#) .
9. Bewersdorf JP, Shallis RM, Gowda L, **Wei W** , Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center

- experience*. *Leukemia & Lymphoma* 2020, 61: 2180-2190. [PMID: 32362171](#) , [PMCID: PMC7603787](#) , [DOI: 10.1080/10428194.2020.1759051](#) .
10. Doroshow D, **Wei W** , Zugazagoitia J, Robbins C, Gupta S, Adamson B, Rimm D. PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC). *Journal Of Clinical Oncology* 2020, 38: 9539-9539. [DOI: 10.1200/jco.2020.38.15_suppl.9539](#) .
 11. Cecchini M, Kortmansky JS, Cui C, **Wei W** , Thumar JR, Uboha NV, Hafez N, Lacy J, Fischbach NA, Sabbath KD, Gomez CM, Sporn JR, Stein S, Hochster HS. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. *Cancer* 2020, 127: 1417-1424. [PMID: 33351187](#) , [PMCID: PMC8085021](#) , [DOI: 10.1002/cncr.33379](#) .
 12. Shallis RM, Bewersdorf JP, Swoboda DM, **Wei W** , Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. *Clinical Lymphoma Myeloma & Leukemia* 2021, 21: e483-e487. [PMID: 33551344](#) , [DOI: 10.1016/j.clml.2021.01.003](#) .
 13. Moutafi M, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross J, Syrigos K, **Wei W** , Puztai L, Rimm D, Vathiotis I. P33.02 Comparison of PD-L1 Protein Expression Between Primary and Metastatic Lesions in Lung Cancer Patients. *Journal Of Thoracic Oncology* 2021, 16: s405-s406. [DOI: 10.1016/j.jtho.2021.01.671](#) .
 14. Peters GW, Tao W, **Wei W** , Miccio JA, Jethwa KR, Cecchini M, Johung KL. Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade. *The Oncologist* 2021, 26: 660-667. [PMID: 33728733](#) , [PMCID: PMC8342580](#) , [DOI: 10.1002/onco.13759](#) .
 15. Moutafi MK, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross JS, Syrigos K, **Wei W** , Puztai L, Rimm DL, Vathiotis IA. Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer. *Journal For ImmunoTherapy Of Cancer* 2021, 9: e002230. [PMID: 33833050](#) , [PMCID: PMC8039214](#) , [DOI: 10.1136/jitc-2020-002230](#) .
 16. Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, **Wei W** , Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. *Clinical Cancer Research* 2021, 27: 4757-4767. [PMID: 34140403](#) , [PMCID: PMC9236708](#) , [DOI: 10.1158/1078-0432.ccr-21-0903](#) .
 17. **Wei W** , Esserman D, Kane M, Zelterman D. Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints. *Statistical Methods In Medical Research* 2021, 30: 1575-1588. [PMID: 34159859](#) , [PMCID: PMC8959087](#) , [DOI: 10.1177/09622802211013062](#) .
 18. Doroshow DB, **Wei W** , Gupta S, Zugazagoitia J, Robbins C, Adamson B, Rimm DL. Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC. *Journal Of Thoracic Oncology* 2021, 16: 2139-2143. [PMID: 34455068](#) , [PMCID: PMC8612948](#) , [DOI: 10.1016/j.jtho.2021.07.032](#) .
 19. Liu Y, Kane M, Esserman D, Blaha O, Zelterman D, **Wei W** . Bayesian local exchangeability design for phase II basket trials. *Statistics In Medicine* 2022, 41: 4367-4384. [PMID: 35777367](#) , [PMCID: PMC10279458](#) , [DOI: 10.1002/sim.9514](#) .

20. Marczyk M, Qing T, O'Meara T, Yagahoobi V, Pelekanou V, Bai Y, Reisenbichler E, Cole KS, Li X, Gunasekharan V, Ibrahim E, Fanucci K, **Wei W**, Rimm DL, Puztai L, Blenman KRM. Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer. *Npj Breast Cancer* 2022, 8: 88. [PMID: 35869114](#), [PMCID: PMC9307813](#), [DOI: 10.1038/s41523-022-00449-3](#).
21. Yu C, Blaha O, Kane M, **Wei W**, Esserman D, Zelterman D. Regression methods for the appearances of extremes in climate data. *Environmetrics* 2022, 33 [DOI: 10.1002/env.2764](#).
22. Bewersdorf J, Shallis R, Sharon E, Caldwell A, **Wei W**, Yacoub A, Madanat Y, Zeidner J, Altman J, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev N, Halene S, Little R, Piekarcz R, Gore S, Kim T, Zeidan A. A Multi-Center Phase Ib Trial of the Histone Deacetylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure. *Blood* 2022, 140: 9084-9086. [DOI: 10.1182/blood-2022-158626](#).
23. Ly C, Blaha O, **Wei W**, Galan A, Kluger H, Ariyan S, Olino K, Clune J. Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. *Frontiers In Oncology* 2023, 12: 1077226. [PMID: 36686728](#), [PMCID: PMC9853390](#), [DOI: 10.3389/fonc.2022.1077226](#).
24. Fanucci K, Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Liu Y, Wang L, **Wei W**, Puztai L, Blenman K. Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial. *Npj Breast Cancer* 2023, 9: 38. [PMID: 37179362](#), [PMCID: PMC10182981](#), [DOI: 10.1038/s41523-023-00535-0](#).
25. Horowitch B, Lee D, Ding M, Martinez-Morilla S, Aung T, Ouerghi F, Wang X, **Wei W**, Damsky W, Sznol M, Kluger H, Rimm D, Ishizuka J. Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma. *Clinical Cancer Research* 2023, 29: 2908-2918. [PMID: 37233452](#), [PMCID: PMC10524955](#), [DOI: 10.1158/1078-0432.ccr-23-0215](#).
26. Merkin R, Schoenfeld D, Djureinovic D, Austin M, Wang M, Qu R, Zhang L, Mann J, **Wei W**, Sun L, Aizenbud L, Destina J, Kluger H. Peripheral blood immune cell and cytokine profiling of patients receiving corticosteroids for immune checkpoint inhibitor-related adverse events: Steroid dose and duration. *Journal Of Clinical Oncology* 2023, 41: e14694-e14694. [DOI: 10.1200/jco.2023.41.16_suppl.e14694](#).
27. Cecchini M, Walther Z, **Wei W**, Hafez N, Pilat M, Boerner S, Durecki D, Eder J, Schalper K, Chen A, LoRusso P. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. *Cancer Research Communications* 2023, 3: 1113-1117. [PMID: 37377610](#), [PMCID: PMC10292219](#), [DOI: 10.1158/2767-9764.crc-22-0485](#).
28. Cecchini M, Zhang J, **Wei W**, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. *Cancer Research Communications* 2023, 3: 1132-1139. [PMID: 37387791](#), [PMCID: PMC10305782](#), [DOI: 10.1158/2767-9764.crc-23-0045](#).
29. Weiss S, Sznol M, Shaheen M, Berciano-Guerrero M, Couselo E, Rodríguez-Abreu D, Boni V, Schuchter L, Gonzalez-Cao M, Arance A, **Wei W**, Ganti A, Hauke R, Berrocal A, Iannotti N, Hsu F, Kluger H. A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with

- Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1. *Clinical Cancer Research* 2023, 30: 74-81. [PMID: 37535056](#) , [PMCID: PMC10767304](#) , [DOI: 10.1158/1078-0432.ccr-23-0475](#) .
30. Schoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, **Wei W** , Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. *Journal For ImmunoTherapy Of Cancer* 2023, 11: e007240. [PMID: 37586773](#) , [PMCID: PMC10432651](#) , [DOI: 10.1136/jitc-2023-007240](#) .
 31. Djureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, **Wei W** , Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech S, Bosenberg M, Jilaveanu L, Kluger H. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. *Molecular Cancer* 2023, 22: 182. [PMID: 37964379](#) , [PMCID: PMC10644655](#) , [DOI: 10.1186/s12943-023-01884-x](#) .
 32. Bewersdorf J, Shallis R, Sharon E, Park S, Ramaswamy R, Roe C, Irish J, Caldwell A, **Wei W** , Yacoub A, Madanat Y, Zeidner J, Altman J, Odenike O, Yerrabothala S, Kovacsovic T, Podoltsev N, Halene S, Little R, Piekarcz R, Gore S, Kim T, Zeidan A. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. *Annals Of Hematology* 2023, 103: 105-116. [PMID: 38036712](#) , [DOI: 10.1007/s00277-023-05552-4](#) .
 33. Wang X, **Wei W** . rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors. *Contemporary Clinical Trials* 2024, 140: 107505. [PMID: 38521384](#) , [DOI: 10.1016/j.cct.2024.107505](#) .
 34. **Wei W** , Blaha O, Esserman D, Zelterman D, Kane M, Liu R, Lin J. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling. *Statistics In Medicine* 2024, 43: 2439-2451. [PMID: 38594809](#) , [PMCID: PMC11325877](#) , [DOI: 10.1002/sim.10077](#) .
 35. **Wei W** , Zhang Y, Roychoudhury S, Initiative T. Propensity score weighted multi-source exchangeability models for incorporating external control data in randomized clinical trials. *Statistics In Medicine* 2024, 43: 3815-3829. [PMID: 38924575](#) , [DOI: 10.1002/sim.10158](#) .